VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Clinical trial NCT01666444 · COMPLETED

Trial details

NCT number: NCT01666444
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer

Start date: 2012-10-31
Primary completion: 2016-07-31
Enrollment: 297

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.